ERBB2 and breast carcinoma: This is not an unreachable goal, as improvements in standardization of pre-analytical factors, analytical performance, and participation in proficiency testing programs led to improvements in the analytic performance and diagnostic accuracy of ER, PR, and HER2 as biomarkers in the management of women with breast cancer, with international consensus as to their clinical utility [137,138,139,140].